Watch the International Gynecologic Cancer Society (IGCS) Educational Webinar to learn why it’s crucial to collect enough tumor before chemotherapy for HRD testing. Supported by Myriad Genetics, this discussion focused on the need for better ovarian cancer biopsies to improve the success of large genomic assays for better patient outcomes.
Homologous recombination deficiency (HRD) is present in around 50% of women with ovarian cancer.1
PARP inhibitors like olaparib or niraparib offer these women better outcomes after initial chemotherapy and are proven to provide the longest progression-free survival interval in a first-line maintenance setting of HRD positive ovarian cancer patients.2
MyChoice CDx Plus is a next generation sequencing-based HRD test which accurately identifies HRD status for every woman with ovarian cancer – by targeting both upstream causes and downstream effects.
MyChoice CDx Plus uses a novel and proprietary measurement called genomic instability score (GIS) which targets three key biomarkers – telomeric allelic imbalance (TAI), loss-of-heterozygosity (LOH), and large-scale transitions (LST).
GIS gives a unique insight into the phenotype of genomic instability associated with HRD, allowing MyChoice CDx Plus to measure downstream effects of HRD5,6,7
MyChoice CDx Plus combines BRCA tumor mutation testing and GIS to go further in identifying:
HRD testing has life-changing consequences for every woman with ovarian cancer, and MyChoice CDx Plus is here to guide treatment decisions for each one
MyChoice CDx Plus identifies patients who benefit (HR=0.33) and do not benefit (HR=1.00) from first-line olaparib combination therapy.2
MyChoice CDx Plus is an HRD test with Level of Evidence
1A to guide first-line PARP inhibitor maintenance.10
The FDA, PMDA and international guidelines trust MyChoice CDx Plus. ESMO recognizes MyChoice CDx Plus is the only scar based HRD test validated in the first-line maintenance setting.10 ASCO recommends it specifically for this setting.11
Fast turnaround time
Clinicians will get a MyChoice CDx Plus result back within two weeks after the pathology lab has received the sample.
To begin using MyChoice CDx Plus to help guide treatment decisions, please fill in the Test Request Form below in your preferred language. Technical specifications are available and also contact information for clinicians, if you would prefer to speak to someone.
If you are a patient, you can speak to your doctor for for more information on HRD testing.
Myriad Genetics MyChoice® CDx Plus is a next generation sequencing based in vitro diagnostic device that provides sequencing and large rearrangement analyses on a panel of genes and/or detects genomic instability using DNA extracted from tumor specimens. Homologous Recombination Deficiency (HRD) is determined by assessing the results of a subset of these genes and/or the Genomic Instability Score (GIS) Status. The test may be used as a companion diagnostic to identify patients who are or may become eligible for treatment with specific therapies in accordance with the approved therapeutic product labeling. Results are to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant solid tumors.